Narayana Hrudayalaya Ltd. (NH) AI Stock Analysis

• Market Cap: ₹374.02B
• Dividend Yield: 0.25%
• Average Volume (3M): 37.76K
• Price to Earnings (P/E): 47.4
• Beta (1Y): 0.67
• Revenue Growth: 12.09%
• EPS Growth: -2.79%
• Country: IN
• Employees: 11,659
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): N/A
• Shares Outstanding: 204,360,800
• 10 Day Avg. Volume: 51,311
• 30 Day Avg. Volume: 37,764
• PEG Ratio: 92.72
• Price to Book (P/B): 9.40
• Price to Sales (P/S): 6.22
• P/FCF Ratio: -354.49
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹1,540.00
• Price Target Upside: -12.32% Downside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 70 Outperform
• Price Target: ₹1,931.00 ▲(9.94% Upside)

Narayana Hrudayalaya Ltd. shows strong financial performance with robust revenue growth and profitability, which is the most significant factor in the overall score. Technical analysis indicates a neutral to slightly bearish trend, and the valuation suggests the stock is expensive, which slightly dampens the overall score.

Narayana Hrudayalaya Ltd. Business Overview & Revenue Model

Company Description

Narayana Hrudayalaya Ltd. (NH) is a leading healthcare provider in India, specializing in cardiac care and other multi-specialty services. Founded by Dr. Devi Shetty in 2000, NH operates a chain of hospitals and healthcare facilities that offer a wide range of medical services, including cardiology, orthopedics, nephrology, and gastroenterology. With a focus on affordable healthcare, the company aims to provide high-quality medical care to patients across various demographics, leveraging advanced technology and skilled medical professionals.

How the Company Makes Money

Narayana Hrudayalaya Ltd. generates revenue primarily through patient services, which include inpatient and outpatient treatments, surgical procedures, and diagnostic services. The company operates on a fee-for-service model, where patients are charged for the services they receive. In addition to direct patient care, NH also earns revenue through partnerships with insurance companies, where they provide medical services to insured patients. Furthermore, NH has expanded its revenue streams by offering telemedicine services and health check-up packages. The company's focus on affordability and quality has attracted a significant patient base, contributing to its overall earnings.

Narayana Hrudayalaya Ltd. Financial Statement Overview

Summary

Narayana Hrudayalaya Ltd. demonstrates strong financial health with robust revenue growth and profitability. The balance sheet reflects prudent financial management, although increasing debt levels need monitoring. Cash flow management is generally effective, despite the recent dip in free cash flow. The company's financial trajectory remains positive, with attention needed on managing future financial risks.

Income Statement

Narayana Hrudayalaya Ltd. has shown a strong financial performance with consistent revenue growth, increasing from 25.8 billion in 2021 to 54.8 billion in 2025. The gross profit margin has improved, indicating better cost management. The net profit margin has remained stable, demonstrating profitability. However, the decline in EBITDA margin from 2024 to 2025 suggests potential cost pressures or investment in growth.

Balance Sheet

The company maintains a healthy balance sheet with a solid equity position. The debt-to-equity ratio is manageable, indicating prudent financial leverage. An increasing equity ratio suggests effective asset management. However, the rising total debt from 2022 to 2025 could pose future financial risks if not managed carefully.

Cash Flow

The cash flow position is relatively stable, with positive operating cash flow consistently over the years. Despite a dip in free cash flow in 2025 due to higher capital expenditure, the overall cash flow management remains robust. The operating cash flow to net income ratio indicates efficient conversion of income into cash, although the negative free cash flow in 2025 warrants attention.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	57.49B	54.83B	48.90B	45.30B	37.01B	25.84B
Gross Profit	24.69B	21.12B	18.41B	16.76B	12.13B	6.42B
EBITDA	12.59B	12.28B	11.02B	9.31B	6.19B	1.43B
Net Income	7.85B	7.90B	7.89B	6.06B	3.42B	-143.04M
Balance Sheet
Total Assets	0.00	72.65B	56.25B	41.62B	31.30B	27.70B
Cash, Cash Equivalents and Short-Term Investments	16.27B	16.27B	11.04B	6.51B	3.01B	2.39B
Total Debt	0.00	24.28B	16.27B	8.84B	7.23B	8.26B
Total Liabilities	-36.28B	36.37B	27.39B	20.30B	16.40B	16.49B
Stockholders Equity	36.28B	36.26B	28.84B	21.31B	14.89B	11.20B
Cash Flow
Free Cash Flow	0.00	-961.81M	959.93M	5.63B	2.34B	2.39B
Operating Cash Flow	0.00	9.86B	10.67B	10.85B	4.85B	3.09B
Investing Cash Flow	0.00	-13.25B	-14.58B	-11.74B	-2.67B	-1.13B
Financing Cash Flow	0.00	5.44B	4.88B	877.41M	-1.59B	-1.98B

Narayana Hrudayalaya Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1756.45
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NH, the sentiment is Positive. The current price of 1756.45 is below the 20-day moving average (MA) of 1771.92, below the 50-day MA of 1769.92, and above the 200-day MA of 1725.25, indicating a bullish trend. The MACD of 8.99 indicates Negative momentum. The RSI at 58.23 is Neutral, neither overbought nor oversold. The STOCH value of 70.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:NH.

Narayana Hrudayalaya Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUROPHARMA	78 Outperform	₹668.50B	19.71	―	0.35%	7.33%	-3.79%
NH	70 Outperform	₹374.02B	47.40	―	0.25%	12.09%	-2.79%
MEDANTA	70 Outperform	₹335.69B	62.80	―	0.04%	15.42%	10.66%
HCG	67 Neutral	₹107.77B	287.35	―	―	16.85%	-29.57%
KIMS	65 Neutral	₹287.00B	76.23	―	―	24.71%	19.17%
FORTIS	64 Neutral	₹769.00B	88.54	―	0.10%	14.04%	32.99%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Narayana Hrudayalaya Ltd. Corporate Events

Narayana Hrudayalaya Expands into UK with New Acquisition

Narayana Hrudayalaya Ltd. has announced its acquisition of UK-based Practice Plus Group Hospitals Limited, marking a significant expansion into the UK healthcare market. This strategic move is expected to enhance Narayana Hrudayalaya’s international presence and strengthen its position in the global healthcare industry, potentially offering new opportunities for growth and collaboration with stakeholders.

Narayana Hrudayalaya Expands UK Presence with Strategic Acquisition

Narayana Hrudayalaya Ltd. has announced the acquisition of Practice Plus Group Hospitals Limited in the UK through its subsidiary Narayana Hrudayalaya UK Ltd. This strategic acquisition, valued at GBP 188.78 million, expands Narayana’s international footprint and enhances its market positioning in the healthcare sector, with Practice Plus Group’s significant presence in the UK comprising multiple hospitals and treatment centers.

Narayana Hrudayalaya Releases Revised Q1 FY26 Investor Presentation

Narayana Hrudayalaya Ltd. has submitted a revised Investor Presentation for the quarter ending June 30, 2025, to the stock exchanges. This update is part of the company’s ongoing efforts to maintain transparency with stakeholders and provide insights into its financial performance and strategic direction.